10.1182/blood-2013-11-538835 - Pomalidomide alone or in combination ...

This document has been corrected

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

10.1182/blood-2013-11-538835

Published Online: 2014-03-20

Journal: Blood•Publisher: American Society of Hematology

Authors: Andrew Belch•Andrzej Jakubowiak•Chaim Shustik•Christian Jacques•Christine Chen•Craig C. Hofmeister•David S. Siegel•David Vesole•Jeffrey Matous•Joseph Mikhael•Kenneth C. Anderson•Kevin Song•Martha Lacy•Min Chen•Mohamed H. Zaki•Nizar Bahlis•Noopur Raje•Paul G. Richardson•Rachid Baz•Ravi Vij•Sagar Lonial•Sundar Jagannath•Suzanne Lentzsch•Zhinuan Yu

This document has been corrected

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

10.1182/blood-2013-11-538835

Published Online: 2014-03-20

Journal: Blood

NOW

2014-05-15•Erratum

Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826-1832.

10.1182/blood-2014-04-566661

* information provided by CrossRef

2014-05-15•Erratum

10.1182/blood-2014-04-566661

* information provided by CrossRef

2014-03-20•Published

2014-05-15•Erratum

10.1182/blood-2014-04-566661

* information provided by CrossRef

This document has been corrected

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

10.1182/blood-2013-11-538835

Published Online: 2014-03-20

Journal: Blood•Publisher: American Society of Hematology